Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지

Inhibitory Effects of Onchungeum on Cytokine Production from Phytohaemagglutinin-stimulated Peripheral blood Mononuclear cells of Behcets Patients

Behcet 환자의 단구세포에서 온청음의 Cytokine 분필억제 효과

  • Lim Hong Jin (Department of Opthamalogy Otoiaryngology and Dermatology, Oriental Medical Collage, Wonkwang University) ;
  • Hwang Choong Yeon (Department of Opthamalogy Otoiaryngology and Dermatology, Oriental Medical Collage, Wonkwang University) ;
  • Chiang Hsueh Chuan (Department of Opthamalogy Otoiaryngology and Dermatology, Oriental Medical Collage, Wonkwang University) ;
  • Kim Nam Kwon (Department of Opthamalogy Otoiaryngology and Dermatology, Oriental Medical Collage, Wonkwang University) ;
  • Kwon Il Ho (Department of Opthamalogy Otoiaryngology and Dermatology, Oriental Medical Collage, Wonkwang University)
  • 임홍진 (원광대학교 한의과대학 와관과교실) ;
  • 황충연 (원광대학교 한의과대학 와관과교실) ;
  • 강학천 (원광대학교 한의과대학 와관과교실) ;
  • 김남권 (원광대학교 한의과대학 와관과교실) ;
  • 권일호 (원광대학교 한의과대학 와관과교실)
  • Published : 2002.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

Behcets disease is a systemic inflammatory disorder. The etiology and pathogenesis of Behcets disease has yet been fully elucidated but might involve immune dysfunction. Cytokines involved in the regulation of inflammatory reactions and immune responses may play a role in the pathogenesis of Behcets disease (BD). Onchungeum is an Oriental herbal medication, which has been successfully used in Korea for the treatment of BD. This report describes modulation effects of Onchungeum on cytokine production from phytohaemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC) of Behcets patients by ELISA. Onchungeum significantly inhibited the production of pro-inflammatory cytokines. TNF-α and IL-1β, compared to absence of Onchungeum (by 52.3 1.4 % inhibition for TNF-α and 113.5 3.3 % for IL-1β, p < 0.001). Onchungeum also inhibited the production of IFN-γ, immunoregulatory Th1 cytokine, by 89.4 0.8 % (p < 0.001). The inhibitory effects of Onchungeum on cytokine production showed dose-dependent manner, and the pre-treatment of 1 mg/ml Onchungeum had better effects than immunosuppressive drug for treatment of BD, cyclosporin A. Our results suggest that Onchungeum treatment for Behcets disease patients may have pharmacologic activities and abilities of regulation of immune and inflammatory responses by cytokine modulation.

Keywords

References

  1. N Engl J Med v.341 Behcet's disease. Sakane T;Takeno M;Suzuki N;Inaba G
  2. Semin, Arthritis Rheum v.27 Behcet's disease. Kaklamani VG;Vaiopoulos G;Kaklamanis PG.
  3. Seminars in Arthritis and Rheumatism. v.8 Behcet Disease. Shimizu, T.;Ehrlich, G.E.; Inaba, G.(et, al)
  4. 금괘요략講義 何任(主編)
  5. 增補萬病回春(下卷) 襲廷賢
  6. 中國醫學史 洪元植
  7. 漢方臨床알레르기 康秉秀
  8. 增補最新漢方臨床學 裵元植
  9. Isr J Med Sci v.31 Elevated serum interleukin 1 receptors and interleukin 1b in patients with Behcet's disease: Correlations with disease activity and severity. Yosipovitch G;Shohat B;Bshara J;Wysenbeek A;Weinberger A.
  10. J Rheumatol v.20 Overproduction of monocyte derived tumor necrosis factor , interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. Mege JL;Dilsen N;Sanguedolce V;Gul A;Bongrand P;Roux H(et al.)
  11. J Rheumatol v.23 Cytokines in Behcet's disease. Sayinalp N;zcebe OI;zdemir O;Haznedaro lu IC;Dundar S, Kirazli
  12. Arthritis and allied conditions: a textbook of rheumatology. v.1 Intermittent and periodic arthritic syndromes. Kastner DL.;Koopman WJ(Ed.)
  13. 臨床皮膚科 雜誌 v.26 no.3 中西醫結合治療白塞病療效觀察 吳之伍(外)
  14. 巢氏諸病源候論 巢元方
  15. 이화의대지 v.6 no.4 Behcet씨 證候群의 臨床的 硏究 김종남
  16. Br. J. Dermatol. v.95 Histological and direct immunofluorescence study of cutaneous hyperreactivity in Behcet disease. Haim S;Sobel JD;Friedman-Birnbaum R; Lichtig C
  17. 方藥合編解說 申載鏞
  18. 醫學入門 v.4;6 이천
  19. 原本東醫寶鑑 許浚
  20. 臨床本草學 辛民敎
  21. 國譯景岳全書(上) v.6 張介賓
  22. J Am Acad Dermatol v.19 Behcet's disease. New perspectives on an enigmatic syndrome. Arbesfeld SJ;Kurban AK.
  23. 診療要覽 金定濟
  24. Int J Clin Pract v.55 Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (Remicade). Bondeson J;Maini RN.
  25. Arthritis Rheum v.44 The combination of tumor necrosis factor- blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Chabaud M;Miossec P.
  26. 增補韓方臨床40年 朴炳坤
  27. Gastroenterology v.120 Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: Case report. Hassard PV;Binder SW;Nelson V;Vasiliauskas EA.
  28. Am J Med v.108 Thalidomide: Current and potential clinical applications. Calabrese L;Fleischer AB.
  29. J Exp Med v.173 Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes. Sampaio EP;Sarno EN;Galilly R;Cohn ZA;Kaplan G.
  30. Clin Exp Immunol v.99 The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral mononuclear cell cultures. McHugh SM;Rifkin IR;Deighton J;Wilson AB;Lachmann PJ;Lockwood CM(et al.)
  31. 原本編註醫學入門(下) v.3 이천
  32. Br J Ophthalmol v.76 Low dose cyclosporin A versus plused cyclophosphamide in Behcet's syndrom: a single masked trial. Ozyazgan Y;Yurdakul S;Yazici H;Tuzun B;Iscimen A;Tuzun Y(et al.)
  33. Ophthalmology v.106 Central nervous system symptoms in patients with Behcet disease receiving cyclosporin therapy. Kotake S;Higashi K;Yoshikawa K;Sasamoto Y;Okamoto T;Matsuda H.